Mixed Bag For Biopharma Funding In 2025: Dispatches From J.P. Morgan, Biotech Showcase

Macro Issues A Challenge, Biotech Fundamentals Positive

 
• By Mandy Jackson
  
Biopharma valuations have leveled off from past declines, but struggle to stay positive (Shutterstock)
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from In Vivo

More from Market Intelligence